/ROIV
ROIV Stock - Roivant Sciences Ltd.
Healthcare|BiotechnologyNASDAQ
$22.41+2.85%
+$0.62 (+2.85%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+24.9%upside
Target: $27.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ROIV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$22.19 – $22.63
TARGET (TP)$28.00
STOP LOSS$20.62
RISK/REWARD1:3.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$23.47
52W Low$8.73
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $29.05M | $32.71M | $61.28M | $55.29M | $23.80M |
| Gross Profit | $28.14M | $31.11M | $48.15M | $46.32M | $21.74M |
| Gross Margin | 96.9% | 95.1% | 78.6% | 83.8% | 91.4% |
| Operating Income | $-1,003,294,000 | $4.50B | $-1,175,318,000 | $-1,351,642,000 | $-1,070,898,000 |
| Net Income | $-171,981,000 | $4.35B | $-1,009,030,000 | $-845,262,000 | $-809,234,000 |
| Net Margin | -592.0% | 13294.2% | -1646.6% | -1528.9% | -3400.9% |
| EPS | $-0.24 | $5.55 | $-1.42 | $-1.26 | $-1.18 |
Company Overview
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$16
Average Target
↓ 27.6% Downside
Now
$11
Low
$16
Average
$20
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 2nd 2025 | Citigroup | Initiation | Buy | $16 |
| July 10th 2025 | Goldman | Resumed | Buy | $19 |
| February 15th 2024 | Wolfe Research | Initiation | Outperform | $17 |
| January 5th 2024 | Piper Sandler | Initiation | Overweight | $20 |
| December 12th 2023 | Deutsche Bank | Initiation | Buy | $14 |
| October 17th 2023 | Guggenheim | Initiation | Buy | $17 |
| June 8th 2023 | BofA Securities | Initiation | Neutral | $10.5 |
Earnings History & Surprises
ROIVBeat Rate
59%
Last 17 quarters
Avg Surprise
-1.9%
EPS vs Estimate
Beats / Misses
10/7
Last 12 quarters
Latest EPS
$-0.28
Q4 2025
EPS Surprise History
Q1 24
+22.2%
$-0.21vs$-0.27
Q2 24
+13.0%
$-0.23vs$-0.26
Q3 24
+26.0%
$-0.18vs$-0.24
Q4 24
-17.4%
$-0.29vs$-0.25
Q1 25
+45.8%
$-0.13vs$-0.24
Q2 25
+16.5%
$-0.22vs$-0.26
Q3 25
+27.9%
$-0.18vs$-0.25
Q4 25
+12.4%
$-0.28vs$-0.32
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 27, 2026 | — | — | — | — |
Q1 2026 | Feb 9, 2026 | $-0.27 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.32 | $-0.28 | +12.4% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.25 | $-0.18 | +27.9% | ✓ BEAT |
Q2 2025 | May 29, 2025 | $-0.26 | $-0.22 | +16.5% | ✓ BEAT |
Q1 2025 | Feb 10, 2025 | $-0.24 | $-0.13 | +45.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.25 | $-0.29 | -17.4% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.24 | $-0.18 | +26.0% | ✓ BEAT |
Q2 2024 | May 30, 2024 | $-0.26 | $-0.23 | +13.0% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $-0.27 | $-0.21 | +22.2% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.26 | $-0.38 | -46.2% | ✗ MISS |
Q2 2023 | Jun 28, 2023 | $-0.41 | $-0.20 | +51.2% | ✓ BEAT |
Q1 2023 | Feb 13, 2023 | $-0.36 | $-0.49 | -36.1% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.41 | $-0.42 | -2.4% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.30 | $-0.48 | -60.0% | ✗ MISS |
Q2 2022 | Jun 28, 2022 | $-0.25 | $-0.39 | -56.0% | ✗ MISS |
Q1 2022 | Feb 14, 2022 | $-0.23 | $-0.41 | -78.3% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.45 | $-0.26 | +42.2% | ✓ BEAT |
Q3 2021 | Sep 21, 2021 | — | — | — | — |
Latest News
Leerink Partners Maintains Outperform on Roivant Sciences, Raises Price Target to $32
📈 PositiveBenzinga•Dec 15, 2025, 08:49 PM
Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $33
📈 PositiveBenzinga•Dec 15, 2025, 05:54 PM
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $26
📈 PositiveBenzinga•Dec 12, 2025, 04:21 PM
Roivant Says Three New Drugs Could Hit the Market in the Next Three Years, Speeds Up Trial Timelines as It Prepares for Major Product Launches ,
📈 PositiveBenzinga•Dec 11, 2025, 12:35 PM
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $26
📈 PositiveBenzinga•Nov 11, 2025, 07:59 PM•Also:
Roivant Sciences Q2 Adj. EPS $(0.28) Beats $(0.33) Estimate, Sales $1.571M Miss $6.947M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 12:02 PM
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $25
📈 PositiveBenzinga•Oct 29, 2025, 08:06 PM•Also:
Roivant Sciences Files For Mixed Shelf Offering; Size Not Disclosed
➖ NeutralBenzinga•Oct 3, 2025, 08:44 PM
Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $24
📈 PositiveBenzinga•Sep 18, 2025, 04:47 PM
Jefferies Maintains Buy on Roivant Sciences, Raises Price Target to $20
📈 PositiveBenzinga•Sep 18, 2025, 02:58 PM
JP Morgan Maintains Overweight on Roivant Sciences, Raises Price Target to $20
📈 PositiveBenzinga•Sep 18, 2025, 01:28 PM•Also:
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $21
📈 PositiveBenzinga•Sep 18, 2025, 01:15 PM
Leerink Partners Maintains Outperform on Roivant Sciences, Raises Price Target to $22
📈 PositiveBenzinga•Sep 18, 2025, 12:56 PM
B of A Securities Maintains Neutral on Roivant Sciences, Raises Price Target to $16.5
➖ NeutralBenzinga•Sep 18, 2025, 12:53 PM
Roivant and Pfizer-backed Priovant post late-stage trial win for dermatomyositis therapy
📈 PositiveSeeking Alpha•Sep 17, 2025, 12:06 PM•Also:
Roivant Sciences shares are trading higher after the company and Priovant reported Phase 3 results for brepocitinib in treating a debilitating skin-muscle disease.
📈 PositiveBenzinga•Sep 17, 2025, 11:49 AM
Roivant And Priovant Report Phase 3 Results For Brepocitinib In Treating Debilitating Skin-Muscle Disease
➖ NeutralBenzinga•Sep 17, 2025, 11:06 AM
Pulmovant Wins Orphan Drug Status In Japan For Experimental Lung Disease Treatment
📈 PositiveBenzinga•Sep 4, 2025, 11:23 AM
Citigroup Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $16
📈 PositiveBenzinga•Sep 2, 2025, 12:02 PM•Also:
Watching Roivant Sciences; Shares Move Higher, Traders Circulate Popular Newsletter Mentions Stock As A Buy
📈 PositiveBenzinga•Aug 26, 2025, 07:03 PM
Frequently Asked Questions about ROIV
What is ROIV's current stock price?
Roivant Sciences Ltd. (ROIV) is currently trading at $22.41 per share. The stock has moved +2.85% today.
What is the analyst price target for ROIV?
The average analyst price target for ROIV is $28.00, based on 1 analyst.
What sector is Roivant Sciences Ltd. in?
Roivant Sciences Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ROIV's market cap?
Roivant Sciences Ltd. has a market capitalization of $15.59 billion, making it a large-cap company.
Does ROIV pay dividends?
No, Roivant Sciences Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASND
Ascendis Pharma A/S
$199.99
Mkt Cap: $12.1B
BBIO
BridgeBio Pharma, Inc.
$76.30
Mkt Cap: $14.5B
EXAS
Exact Sciences Corporation
$101.82
Mkt Cap: $19.3B
IONS
Ionis Pharmaceuticals, Inc.
$79.57
Mkt Cap: $12.6B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
RPRX
Royalty Pharma plc
$38.60
Mkt Cap: $16.8B
RVMD
Revolution Medicines, Inc.
$78.78
Mkt Cap: $15.2B
SMMT
Summit Therapeutics Inc.
$17.82
Mkt Cap: $13.3B
Explore stocks similar to ROIV for comparison